title: [Membranous nephropathy].
abstract: Membranous nephropathy is characterized by immune complex deposits on the outer side of the glomerular basement membrane. Activation of complement and of oxidation lead to basement membrane lesions. The most frequent form is idiopathic. At 5 and 10 years, renal survival is around 90 and 65% respectively. A prognostic model based on proteinuria, level and duration, progression of renal failure in a few months can refine prognosis. The urinary excretion of C5b-9, β2 and α1 microglobuline and IgG are strong predictors of outcome. Symptomatic treatment is based on anticoagulation in case of nephrotic syndrome, angiotensin conversion enzyme inhibitors, angiotensin II receptor blockers and statins. Immunosuppressive therapy should be discussed for patients having a high risk of progression. Corticoids alone has no indication. Treatment should include a simultaneous association or more often alternating corticoids and alkylant agent for a minimum of 6 months. Adrenocorticoid stimulating hormone and steroids plus mycophenolate mofetil may be equally effective. Steroids plus alkylant decrease the risk of end stage renal failure. Cyclosporine and tacrolimus decrease proteinuria but are associated with a high risk of recurrence at time of withdrawal and are nephrotoxic. Rituximab evaluated on open studies needs further evaluations to define its use.
authors: Service de néphrologie, groupe hospitalier Pitié-Salpêtrière, 83, boulevard de l'Hôpital, 75013 Paris, France. Electronic address: lucile.mercadal@psl.aphp.fr.
authors: Lucile
authors: L
authors: Mercadal
mesh_terms: D003663:Decision Trees; D015433:Glomerulonephritis, Membranous / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D006801:Humans
keywords: Ciclosporine; Corticoids; Corticoïdes; Cyclophosphamid; Cyclophosphamide; Cyclosporine; Glomérulopathie extramembraneuse; Membranous nephropathy; Mycophenolate mofetil; Néphrite de Heymann; Rituximab; Tacrolimus